One milligramme of acetylsalicylic acid daily inhibits platelet thromboxane A2 production.
To seek the lowest dose of acetylsalicylic acid (ASA) capable of inhibiting platelet thromboxane A2 (TxA)2 production, 18 healthy volunteers ingested 9 mg, 3 mg or 1 mg of ASA/day for twenty days and the release of TxB2 (a metabolite of TxA2) during the spontaneous clotting of blood was measured by radioimmunoassay. In addition, the production of prostacyclin (epoprostenol, PGI2) was investigated by measuring the urinary excretion of its break-down product, 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) by radioimmunoassay. Significant inhibition of platelet TxA2 production was seen from the 15th day of treatment onwards with 1 mg of ASA (maximally 15%), from the 4th day of treatment onwards with 3 mg of ASA (maximally 40%), from the 1st day of treatment onwards with 9 mg of ASA (maximally 67%). No ASA dose changed platelet counts or urinary 6-keto-PGF1 alpha excretion. One mg of ASA daily, is the lowest dose ever shown to inhibit platelet TxA2 production.
D001241:Aspirin / Q000008:administration & dosage*; D001792:Blood Platelets / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010976:Platelet Count; D013928:Thromboxane A2 / Q000096:biosynthesis* / Q000652:urine; D013931:Thromboxanes / Q000096:biosynthesis*
D013931:Thromboxanes; D013928:Thromboxane A2; D001241:Aspirin